Shugeng Gao

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Bin Qiu, Wei Guo, Fan Zhang et al. · Nature Communications · 2021 · 268 citations · Full text

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee et al. · The Lancet · 2024 · 173 citations · Full text

Oncology, Adjuvant Pembrolizumab, Clinical Trials +8

Development and validation of an immune‐related prognostic signature in lung adenocarcinoma

Sijin Sun, Wei Guo, Zhen Wang et al. · Cancer Medicine · 2020 · 168 citations · Full text

Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Jufang Shi, Le Wang, Ning Wu et al. · Lung Cancer · 2018 · 132 citations

Medical Service Utilization, Oncology, Cancer Epidemiology +10

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer

Yanhua Tian, Qingqing Li, Zhenlin Yang et al. · Signal Transduction and Targeted Therapy · 2022 · 130 citations · Full text